Sanofi’s third-quarter vaccine sales fell 7.2%, Reuters has reported. But CEO Chris Viehbacher has ascribed the slump in sales to a manufacturing issue at Sanofiâ€™s Toronto vaccine plant, which led to a shortage in the US market of the company’s paediatric vaccines.
The manufacturing problem has now been resolved and shipping of the vaccines has restarted. Sanofi doesn’t expect its sales to take any further hit from the Toronto problem, and expects a record flu season in the second half of the year.
Sanofi was recently able to demonstrate the actual clinical benefit of Fluzone High-Dose compared to standard Fluzone, paving the way for the company to add the superiority claim to the Fluzone High-Dose label. Also under the Fluzone umbrella is Sanofi’s Fluzone Quadrivalent vaccine, which the French company began shipping recently for use in the 2013-2014 season in the US.
Read more at Reuters >
If you want to know more about vaccines, and meet innovators, disruptors and influencers from across the vaccine research, development and technology landscape, find out about the World Vaccine Congress, 24-26 March 2014, Washington DC.